MolMed SpA restored a measure of confidence to European biotechnology by netting €50.1 million (US$76 million) in the sector's first IPO of this year. Shares will begin trading today on the Mercato Telematico Azionario, the electronic share-trading platform administered by Milan, Italy-based Borsa Italiana SpA. (BioWorld International) Read More
